Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up

BACKGROUND: Anaplastic lymphoma kinase (ALK) translocations in metastatic non-small cell lung cancer (3% to 7%) predict for response to ALK-inhibitors (eg, alectinib, first line), resulting in a 5-year survival rate of ∼60% and median progression-free survival of 34.8 months. Although the overall to...

Descripción completa

Detalles Bibliográficos
Autores principales: Pruis, Melinda A., Veerman, G.D. Marijn, Hassing, H. Carlijne, Lanser, Daan A.C., Paats, Marthe S., van Schaik, Ron H.N., Mathijssen, Ron H.J., Manintveld, Olivier, Dingemans, Anne-Marie C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982223/
https://www.ncbi.nlm.nih.gov/pubmed/36875894
http://dx.doi.org/10.1016/j.jaccao.2022.09.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982223/
https://www.ncbi.nlm.nih.gov/pubmed/36875894
http://dx.doi.org/10.1016/j.jaccao.2022.09.006

Ejemplares similares